Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience

scientific article

Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1111/J.1365-2516.2006.01196.X
P698PubMed publication ID16445813

P2093author name stringG Dolan
P2860cites workPreclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patientQ34339769
Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitationQ43627159
New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' OrganisationQ45884605
GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS.Q45886952
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.Q51037857
P921main subjectemerging pathogenQ108429945
Creutzfeldt-Jakob diseaseQ49989
hemophiliaQ134003
P304page(s)16-20; discussion 26-8
P577publication date2006-03-01
P1433published inHaemophiliaQ15753375
P1476titleClinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience
P478volume12 Suppl 1

Reverse relations

cites work (P2860)
Q37303186Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
Q36488803Blood safety and the choice of anti-hemophilic factor concentrate
Q37234113Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells
Q36638892Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK?
Q24235721Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically)
Q24242392Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) through medical treatment (iatrogenically)
Q38527508Recombinant activated factor VII: 30 years of research and innovation

Search more.